Lotus Pharmaceutical(1795:TT), a multinational pharmaceutical company, reported its financial results for the third quarter ended 30 September 2022.
Lotus is one of the key investments in Aztiq's portfolio and has been built over the past 10 years by Aztiq's key executives.
I am very happy to share such a record setting quarter that will most certainly lead to the most profitable year in Lotus’s history. With Lenalidomide launch in the US, the largest market in the world and the first delivery to Brazil, the largest market in South America, Lotus has achieved major milestones of its transformation to a global oncology player. I am confident that the team will continue to set records with further achievements driving sustainable growth.
Róbert Wessman, Chairman of Lotus
Third quarter 2022 is the best quarter ever in the Company’s history majorly driven by the successful launch of Lenalidomide in the US – the biggest launch in Lotus history so far. Basic EPS for the first nine months ended 30 September 2022 totaled NT$10.96, setting the course for the Company to achieve another record year in 2022.
Consolidated net sales were NT$5,389 million, representing a growth of 85.2% over the last quarter and 76.3% versus prior year period.
Export Business was the main growth driver, contributed by the successful launch of Lenalidomide (generic of Revlimid) in the US, as well as the first delivery to Brazil, the largest market in Latin America. Sales from Export increased 245% compared to last quarter and 183% compared to same period last year.
Asian Business continued to grow for the third consecutive quarter, 3.2% over last quarter, also 10.8% over the same period last year. Key brands in major markets, including Korea, Taiwan, and Thailand, continued the growth momentum.
Gross margin rose to 67.9%, driven by product mix with higher contribution from more profitable export oncology products during the quarter.
Comparing to the prior year, operating profits grew by 353%, to NT$2,641 million, with 49.0% operating margin for the quarter, mainly driven by higher gross margin.
Historic high third quarter EPS of NT$7.97 and first 9 months basic EPS of NT$10.96
Lotus’s success during recent years provides necessary financial resources to continue investing in new products, new partnerships, entering new markets and, at the same time, provide returns to our shareholders. We believe this is the beginning of a new chapter of Lotus’s growth story.
Petar Vazharov, Chief Executive Officer of Lotus
Lotus will continue to build US pipeline and the recent tentative approval of the generic Midostaurin softgel capsules from the US FDA is a testimony to that. Lotus believes that this is a potential first-to-file opportunity and expects to launch the generic Midostaurin softgel capsules subject to the intellectual property clearance in the US. Another important milestone occurred during the quarter is Lenalidomide filing in Japan, and similar to the US, we are ramping up a robust pipeline of products for Japan market based on strategic partnership.
For further information visit Lotus newsroom.